EN DE
Watch Nanotech Indonesia Global Tbk PT for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Nanotech Indonesia Global Tbk PT (NANO) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Nanotech Indonesia Global Tbk PT stock IDR 26, price IDR 24, upside +10.0%, quality 59 out of 100. Rating: fairly valued. Calculated from audited financials with 23 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare ID · ISIN ID1000166606

NI Nanotech Indonesia Global Tbk PT logo Thin data Nov 9, 2026

Nanotech Indonesia Global Tbk PT

NANO · JK
Fairly valued, in a downtrend

The stock costs about what our calculation considers fair.

Low debt
Generates free cash flow
Ranks above peers (9/13)
Costs just 9.2 times its yearly profit.
Fair value 26.40 IDR · Fairly valued
Quality 59/100
Mixed Growth (revenue 5y +70.1 %/yr in IDR)
Thin margins · 1.8% net margin (TTM)
Narrow moat 26/100 · thin data
Thin data
Quality growth
Watch Nanotech Indonesia Global Tbk PT for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

176.00 IDR 13.00 IDR Fair Value 26.40 IDR Mar 2022 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.

How to read this chart

56‑month range 13.00 IDR – 176.00 IDR · fair‑value band 18.49 IDR – 34.33 IDR · the 24.00 IDR price screens below the 26.40 IDR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 9, 2026.

Follow Nanotech Indonesia Global Tbk PT in your weekly email

Every Wednesday you see whether Nanotech Indonesia Global Tbk PT is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

PT Nanotech Indonesia Global Tbk provides technology and engineering research and development services in Indonesia. The company operates in two segments, Service and Trading.

Show moreShow less

It engages in travel agencies, bureau, tourism, nature tourism information, management consulting, employment, and education businesses, as well as operates in the manufacturing and trading industries. The company was incorporated in 2019 and is headquartered in South Tangerang, Indonesia.

PT Nanotech Indonesia Global Tbk is a subsidiary of PT Nanotech Investama Sedaya.

Stock analysis

Nanotech Indonesia Global Tbk PT (NANO) currently trades at 24.00 IDR, while our model-based Fair Value estimate is 26.40 IDR, so the stock looks roughly fairly valued today (gap 9.1%).

Show more

Valuation

Bull case: the Growth DCF group reads highest at a median of 119.38 IDR per share, and 10 of the 23 models we run sit above the 24.00 IDR price.

Bear case: the Multiples group reads lowest at 9.75 IDR, and 13 of the 23 models stay below the price. Data coverage for this calculation is low.

Scenario range: 18.49 IDR (bear) to 34.33 IDR (bull), the price of 24.00 IDR sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 59/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Nanotech Indonesia Global Tbk PT reported revenue of 72.2B IDR in FY2025 versus 26.8B IDR in FY2021, a compound +28.1%/yr. Reported net income was 2.1B IDR in FY2025, compounding +13.4%/yr from FY2021.

Key figures

Market cap 103B IDR (≈ $5.7M) Micro · P/E ratio 9.2 · P/S ratio 0.26 · EPS (TTM) 2.61 IDR · Net margin 2.8% · Return on equity 1.6% · Return on assets (EBIT) 2.5% (5-year average) · Operating margin 1.8%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 26 out of 100 (low confidence).

What moves the price

The share trades about 62% below its 52-week high and 20% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −15% fair-value upside, at 10%, NANO screens cheaper than that median.

Fair Value models

Bear 18.49 IDR Fair Value 26.40 IDR Bull 34.33 IDR
Price 24.00 IDR · Upside +10.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (2.24 IDR per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF 108.74 IDR 161.21 IDR 319.98 IDR 77
Growth DCF 101.96 IDR 181.20 IDR 306.43 IDR 76
5Y EBITDA Exit 45.96 IDR 64.07 IDR 98.95 IDR 75
All 23 models by family
DCF Models
FCF DCF 108.74 IDR 161.21 IDR 319.98 IDR 77
5Y Revenue Exit 39.08 IDR 50.17 IDR 71.99 IDR 73
5Y EBITDA Exit 45.96 IDR 64.07 IDR 98.95 IDR 75
5Y P/E Exit 39.56 IDR 60.44 IDR 84.28 IDR 71
10Y Revenue Exit 61.79 IDR 95.92 IDR 105.80 IDR 68
10Y EBITDA Exit 66.76 IDR 109.76 IDR 172.85 IDR 67
10Y P/E Exit 62.38 IDR 96.88 IDR 143.22 IDR 63
Earnings-Based
Graham-Dodd 3.26 IDR 22.73 IDR 31.90 IDR 63
Lynch FV 10.82 IDR 15.46 IDR 20.10 IDR 61
PEG = 1.0 10.82 IDR 15.46 IDR 20.10 IDR 57
EPV 6.16 IDR 6.96 IDR 7.63 IDR 74
Multiples
P/E Multiple 7.91 IDR 10.55 IDR 13.18 IDR 63
P/S Multiple 6.11 IDR 8.15 IDR 10.19 IDR 58
P/B Multiple 132.27 IDR 176.36 IDR 220.45 IDR 55
EV/EBIT 5.80 IDR 8.95 IDR 12.11 IDR 65
EV/EBITDA 13.30 IDR 18.96 IDR 24.61 IDR 67
EV/Revenue 3.09 IDR 5.99 IDR 8.88 IDR 51
Asset-Based
NCAV (Graham) 9.28 IDR 14.05 IDR 17.57 IDR 54
Growth DCF
Growth DCF 101.96 IDR 181.20 IDR 306.43 IDR 76
Rev-Margin DCF 41.65 IDR 57.56 IDR 91.31 IDR 72
Economic Profit
Residual Income 22.56 IDR 23.55 IDR 25.73 IDR 71
ROIC Compounder 6.16 IDR 6.96 IDR 7.63 IDR 72
Growth Earnings
Growth-Adj P/E 14.60 IDR 20.85 IDR 27.11 IDR 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 59/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 19
How much profit the company makes from its sales and capital
Quality Growth 44
Are margins and returns getting better?
Cashflow 93
Do the profits arrive as real cash?
Financial strength 60
Debt, balance sheet and risk of trouble
Investment 72
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 11
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 5
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 90/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+62.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+70.1%
What shareholders gained per year (last 5 years), in IDR (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip. Measured in IDR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−19.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year−19.1%
Dividend (yield on the price)0.0%
Profit margin 2019 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.19% → 4%
2025 sits 52% above its own trend. The rate follows the median trend of the last 5 years, not that single year.

Growth Forecast

Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−22.1%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Indonesia: IMF forecast 2.6% a year to 2030, 2.9% from 2016 to 2025) that is about −24.1% a year for the price.

Watch NANO, get fair value alerts →

Compare Nanotech Indonesia Global Tbk PT with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 318 stocks

Beats the industry median on 8/12 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 59 · Above median
Fair Value upside +10.0% · Top 25%
Profitability
Return on equity (12 months) 1.6% · Below median
Return on assets 1.0% · Below median
Net margin (12 months) 1.8% · Below median
Operating margin (12 months) 1.8% · Below median
Growth and dividend
Revenue growth (quarter YoY) 315.6% · Top 25%

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/E (12 months) 9.2× · Cheapest 25%
P/B 0.61× · Cheapest 25%
P/S (12 months) 0.43× · Cheapest 25%
Price / free cash flow (fiscal year) 3.4× · Cheapest 25%
EV/EBITDA 11.7× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)47 · sector 6
FUTURE (revenue growth)100 · sector 36
PAST (return on equity)6 · sector 17
HEALTH (low debt)100 · sector 98
DIVIDEND (yield)0 · sector 34

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Stryker Corporation SYK $325.87 $358.46 +10% vs NANO
Boston Scientific Corporation BSX $42.75 $47.03 +10% vs NANO
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥184.15 ¥202.57 +10% vs NANO
DexCom, Inc DXCM $79.41 $87.35 +10% vs NANO
GE HealthCare Technologies Inc GEHC $82.38 $69.92 −15% vs NANO
Edwards Lifesciences Corporation EW $102.14 $81.94 −20% vs NANO
Siemens Healthineers AG SHL €44.66 €34.51 −23% vs NANO
Abbott Laboratories, ABT $109.93 $75.28 −32% vs NANO
Medtronic plc MDT $101.80 $65.61 −36% vs NANO
Koninklijke Philips N.V PHIA €27.33 €15.23 −44% vs NANO

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Nanotech Indonesia Global Tbk PT: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Nanotech Indonesia Global Tbk PT Fair Value". https://www.fairvalue-calculator.com/stock/NANO

Frequently asked questions

Is Nanotech Indonesia Global Tbk PT (NANO) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of 26.40 IDR versus a price of 24.00 IDR, about +10% upside (fairly valued).
What is the fair value of NANO?
Our model-based fair value for Nanotech Indonesia Global Tbk PT is 26.40 IDR (as of Nov 9, 2026), built from audited fundamentals. The current price: 24.00 IDR.
What is the quality score of NANO?
Nanotech Indonesia Global Tbk PT has a Quality Score of 59/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Nanotech Indonesia Global Tbk PT (NANO)?
Our model-based price target is the fair value of 26.40 IDR (as of Nov 9, 2026) from 23 valuation models. Cautious scenario 18.49 IDR, optimistic scenario 34.33 IDR. It is a calculation from audited fundamentals, not an analyst target.
What is the Nanotech Indonesia Global Tbk PT stock forecast for 2026?
Our models put fair value at 26.40 IDR, about +10% upside versus a price of 24.00 IDR (fairly valued). Cautious scenario 18.49 IDR, optimistic scenario 34.33 IDR. The calculation is refreshed regularly with new filings.
What growth is priced into Nanotech Indonesia Global Tbk PT (NANO)?
For today's price to be fair in a discounted-cash-flow model, Nanotech Indonesia Global Tbk PT would have to grow free cash flow by -22.1 % per year for five years (discount rate 10.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +35.1 % per year. As of Nov 9, 2026.
What discount rate (WACC) does the fair value of NANO use?
Our models discount Nanotech Indonesia Global Tbk PT at 10.5 %: a base by market capitalisation (nano), damped by beta 0.06, country premium for Indonesia. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Nanotech Indonesia Global Tbk PT that is -22.1 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (10.5 %) and the same formula as our fair value.
How much growth has Nanotech Indonesia Global Tbk PT (NANO) delivered so far?
Over the past 5 years revenue at Nanotech Indonesia Global Tbk PT grew +35.1 % a year. The price currently implies free-cash-flow growth of -22.1 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Nanotech Indonesia Global Tbk PT (NANO) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Nanotech Indonesia Global Tbk PT (-22.1 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Nanotech Indonesia Global Tbk PT (NANO)?
The free-cash-flow yield on the price is 29.63 %: that much free cash flow Nanotech Indonesia Global Tbk PT produces per unit of market value. When it exceeds the discount rate of our models (10.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Nanotech Indonesia Global Tbk PT (NANO)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Nanotech Indonesia Global Tbk PT it is 26.40 IDR per share (as of Nov 9, 2026), against a price of 24.00 IDR. It is the blended result of 23 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Nanotech Indonesia Global Tbk PT stock overvalued or undervalued in 2026?
As of Nov 9, 2026, NANO trades below its calculated fair value: price 24.00 IDR, fair value 26.40 IDR, a gap of about +10% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of NANO?
No. The price is what the market pays today (24.00 IDR); the fair value is what the company's own numbers justify (26.40 IDR). For Nanotech Indonesia Global Tbk PT the two are 2.40 IDR per share apart. That gap is exactly why we show both numbers side by side.
How much is Nanotech Indonesia Global Tbk PT worth?
The market values Nanotech Indonesia Global Tbk PT at about 103B IDR (market capitalisation, as of Nov 9, 2026). Per share that is 24.00 IDR; our models calculate a fair value of 26.40 IDR per share.
What do the bullish and bearish scenarios say about NANO?
Our models span a range for Nanotech Indonesia Global Tbk PT: cautious scenario 18.49 IDR, base 26.40 IDR, optimistic 34.33 IDR per share (as of Nov 9, 2026, price 24.00 IDR). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of NANO?
Nanotech Indonesia Global Tbk PT trades at a price-to-earnings ratio of 9.2 (as of Nov 9, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 26.40 IDR is built from several models across several years. Other multiples: P/B 0.6, P/S 0.4, EV/EBITDA 11.7.
How solid is the balance sheet of Nanotech Indonesia Global Tbk PT (NANO)?
Balance-sheet figures for Nanotech Indonesia Global Tbk PT (as of Nov 9, 2026): return on equity 1.6%. They feed the Quality Score of 59/100, which measures business quality independently of the share price.
How far is NANO from its 52-week high?
Nanotech Indonesia Global Tbk PT trades at 24.00 IDR, about 62% below its 52-week high of 63.00 IDR and 20% above the low of 20.00 IDR (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 26.40 IDR is for.
Which stocks are comparable to Nanotech Indonesia Global Tbk PT?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Nanotech Indonesia Global Tbk PT stock attractive at the current price?
The data as of Nov 9, 2026: price 24.00 IDR, calculated fair value 26.40 IDR (+10%), Quality Score 59/100, from 23 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of NANO calculated?
We run Nanotech Indonesia Global Tbk PT through 23 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 26.40 IDR builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Nanotech Indonesia Global Tbk PT currently trades 9% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Nanotech Indonesia Global Tbk PT (NANO)?
The closing price on Nov 6, 2026 was 24.00 IDR. Our model-based fair value is 26.40 IDR, about +10% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Nanotech Indonesia Global Tbk PT right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (18.49 IDR to 34.33 IDR) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Nanotech Indonesia Global Tbk PT

How large is the market capitalisation of Nanotech Indonesia Global Tbk PT (NANO)?
The market capitalisation of Nanotech Indonesia Global Tbk PT is 103B IDR (≈ $5.7M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Nanotech Indonesia Global Tbk PT (NANO)?
The price-to-sales ratio of Nanotech Indonesia Global Tbk PT is 0.26 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Nanotech Indonesia Global Tbk PT (NANO)?
Earnings per share at Nanotech Indonesia Global Tbk PT are 2.61 IDR (price ÷ EPS = P/E 9.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Nanotech Indonesia Global Tbk PT (NANO)?
The net margin of Nanotech Indonesia Global Tbk PT is 2.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Nanotech Indonesia Global Tbk PT (NANO)?
The return on equity (ROE) of Nanotech Indonesia Global Tbk PT is 1.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Nanotech Indonesia Global Tbk PT (NANO)?
On an EBIT basis the return on assets of Nanotech Indonesia Global Tbk PT is 2.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Nanotech Indonesia Global Tbk PT (NANO)?
The operating margin of Nanotech Indonesia Global Tbk PT is 1.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Nanotech Indonesia Global Tbk PT (NANO)?
Revenue at Nanotech Indonesia Global Tbk PT is growing +316% versus a year earlier (3y avg +17.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Nanotech Indonesia Global Tbk PT (NANO)?
Earnings per share at Nanotech Indonesia Global Tbk PT are growing +493% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Nanotech Indonesia Global Tbk PT (NANO) carry?
The net debt of Nanotech Indonesia Global Tbk PT is 15.7B IDR (fiscal year 2025, ≈ 0.5 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Nanotech Indonesia Global Tbk PT in the live analysis

One click puts Nanotech Indonesia Global Tbk PT on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.